Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study
Anti-COVID-19 vaccination may have functional implications for immune checkpoint inhibitor treatment in patients with cancer. This study was undertaken to determine whether the safety or efficacy of anti-PD-1 therapy is reduced in patients with cancer during COVID-19 vaccination. A large multicenter...
Saved in:
| Main Authors: | Yang Yang, Junping Yin, Jian Li, Bo Liu, Ming Li, Qiao Huang, Xianglin Yuan, Christian Kurts, Guangyuan Hu, Qi Mei, Xi Tang, Alexander Böhner, Amy Bryant |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-03-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/3/e004157.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study
by: Lihui Lin, et al.
Published: (2025-07-01) -
Real-world efficacy of PD-1/PD-L1 inhibitors in patients with advanced pulmonary neuroendocrine carcinoma: a single-center analysis
by: Wanchen Zhai, et al.
Published: (2024-10-01) -
Management of immune-related adverse events under PD-1/PD-L1 inhibitors: Insights from a Moroccan real-world experience
by: Inès Cherradi, et al.
Published: (2025-01-01) -
Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors
by: Juan Chen, et al.
Published: (2024-07-01) -
PD-1/PD-L1 inhibitors monotherapy vs. combination therapy in elderly advanced NSCLC: a real-world study and nomogram for survival prognosis
by: Yunye Mao, et al.
Published: (2025-07-01)